We are live on
!
Find out more
RI
RTW Investments Portfolio holdings
AUM
$10B
1-Year Est. Return
135.35%
This Fund
S&P 500
This Quarter
Est. Return
+13.47%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$10B
AUM Growth
+$66.4M
(+0.67%)
Cap. Flow
+$419M
Cap. Flow
% of AUM
4.17%
Top 10 Holdings %
Top 10 Hldgs %
49.99%
Holding
98
New
7
Increased
30
Reduced
13
Closed
10
Top Buys
| 1 |
CG Oncology
CGON
|
+$282M |
| 2 |
Celcuity
CELC
|
+$271M |
| 3 |
Erasca
ERAS
|
+$189M |
| 4 |
Tango Therapeutics
TNGX
|
+$164M |
| 5 |
iRhythm Holdings
IRTC
|
+$70.2M |
Top Sells
| 1 |
Penumbra
PEN
|
+$269M |
| 2 |
Axsome Therapeutics
AXSM
|
+$162M |
| 3 |
Insulet
PODD
|
+$92.3M |
| 4 |
MASI
Masimo
MASI
|
+$88.9M |
| 5 |
APLS
Apellis Pharmaceuticals
APLS
|
+$85.8M |
Sector Composition
| 1 | Healthcare | 99.92% |
| 2 | Financials | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Madrigal Pharmaceuticals
MDGL
$12.7B
| $1.04B | 10.38% |
1,993,687
| – | – |
|
2
Insmed
INSM
$23.8B
| $792M | 7.88% |
4,842,880
+1
| +0% | +$154 |
|
3
Protagonist Therapeutics
PTGX
$8.71B
| $533M | 5.31% |
5,059,053
| – | – |
|
4
PTC Therapeutics
PTCT
$6.54B
| $528M | 5.25% |
7,746,415
| – | – |
|
5
argenx
ARGX
$54B
| $518M | 5.16% |
709,446
+35,949
| +5% | +$28.1M |
|
|
6
CG Oncology
CGON
$6.44B
| $473M | 4.7% |
6,984,808
+4,972,681
| +247% | +$282M |
|
|
7
Celcuity
CELC
$4.46B
| $347M | 3.45% |
3,039,621
+2,489,461
| +452% | +$271M |
|
|
8
Tango Therapeutics
TNGX
$4.93B
| $278M | 2.77% |
13,300,620
+11,809,392
| +792% | +$164M |
|
|
9
Erasca
ERAS
$6.61B
| $261M | 2.6% |
16,157,175
+16,010,524
| +10,917% | +$189M |
|
10
Natera
NTRA
$39.7B
| $250M | 2.49% |
1,250,000
-250,000
| -17% | -$53.8M |
|
11
RadNet
RDNT
$4.83B
| $239M | 2.38% |
4,285,000
+346,500
| +9% | +$23.7M |
|
12
Tarsus Pharmaceuticals
TARS
$2.51B
| $235M | 2.34% |
3,346,025
+10,705
| +0.3% | +$748K |
|
13
Apogee Therapeutics
APGE
$10.2B
| $234M | 2.33% |
2,782,097
+70,000
| +3% | +$5.08M |
|
14
Spyre Therapeutics
SYRE
$8.86B
| $210M | 2.09% |
4,171,996
| – | – |
|
15
Cogent Biosciences
COGT
$6.72B
| $210M | 2.09% |
5,458,675
-2,133,566
| -28% | -$78.8M |
|
|
16
iRhythm Holdings
IRTC
$3.72B
| $197M | 1.96% |
1,668,500
+486,510
| +41% | +$70.2M |
|
17
Stoke Therapeutics
STOK
$1.86B
| $183M | 1.82% |
5,623,525
+76,669
| +1% | +$2.51M |
|
18
Cytokinetics
CYTK
$11.2B
| $179M | 1.78% |
2,721,158
| – | – |
|
19
Acadia Pharmaceuticals
ACAD
$4.44B
| $159M | 1.58% |
7,144,524
| – | – |
|
20
Establishment Labs
ESTA
$2.67B
| $151M | 1.5% |
2,655,695
+66,864
| +3% | +$4.57M |
|
|
APLS
21
DELISTED
Apellis Pharmaceuticals
APLS
| $148M | 1.48% |
3,685,045
-3,981,719
| -52% | -$85.8M |
|
22
Immunocore
IMCR
$1.76B
| $147M | 1.46% |
4,869,798
| – | – |
|
23
Repligen
RGEN
$8.35B
| $142M | 1.41% |
1,206,000
+142,000
| +13% | +$19.8M |
|
24
Neurocrine Biosciences
NBIX
$17.3B
| $140M | 1.39% |
1,062,072
| – | – |
|
25
Guardant Health
GH
$21.6B
| $137M | 1.36% |
1,481,033
| – | – |
|
Similar funds
BEI
ECM
BHCM
MG
LWCFA
HRCM
RA
VNIM